Connect with us

Business

Covid-19 crisis prompts India to look for global partners in health care

Published

on

Covid-19 crisis prompts India to look for global partners in health care

As India shifts its focus to the pharmaceutical and medical devices industries amid the Covid-19 pandemic, it is actively reaching out to several countries, including Japan, seeking to attract investments in manufacturing and joint venture projects, according to officials and industry executives.

India sees an investment potential ofRs 70,000 crore in the medical devices industry alone over the next five years.

The government is targeting 1,200 technical collaborations between Japanese companies and Indian investors for over 42,000 crore, 200 joint ventures with overseas investors forRs 14,000 crore, and another 14,000-crore investment from about 50 multinational companies.

Advertisement

This was discussed during a webinar organised by the Indian Embassy in Tokyo, along with the Department of Pharmaceuticals, and it had over 150 participants from both countries. P D Vaghela, secretary, Department of Pharmaceuticals , who was also present in the webinar, said Japanese companies were interested in investing in the API (active pharmaceutical ingredient) space, and could also explore joint ventures in the medical devices segment.

ALSO READ: Three employees of Cadila Pharmaceuticals die of coronavirus in Gujarat

Advertisement

 

Speaking to Business Standard, Sudarshan Jain, secretary-general of the Indian Pharmaceutical Alliance (IPA), said companies like Eisai Pharmaceuticals had been operating in the country since the early 2000s and their experience had been good.

 

Advertisement

“India can be a low-cost manufacturing base for Japan. We have skilled manpower and at lower costs. India is one of the largest suppliers of generic medicines to the US; it can do the same for Japan,” Jain said.

 

He said partnerships or investments could be in different kinds of projects. One is where a Japanese company sets up a manufacturing base here for exporting to other countries, or it can export to Japan. Secondly, they can also invest in Indian companies that make drugs. Moreover, with India’s renewed focus on growing its API production, there are a lot of investment opportunities for Japanese majors. Eisai, for example, makes APIs. “The Indian government is now offering production-linked incentives for large API production units and this can be an area of collaboration,” Jain said.

Advertisement

 

The DoP secretary has asked the Japanese industry to get in touch with the pharma bureau, set up to guide potential investors. Last month, the medical devices industry here had requested the Indian ambassador to invite the Japanese to shift factories from China to India, informed Rajiv Nath, forum coordinator of the Association of Indian Medical Device Industry (AiMeD).

ALSO READ: Coronavirus LIVE: Sikkim detects first case; Ahmedabad 24 deaths in a day

Advertisement

 

Pharma majors like Sun Pharma, Wockhardt, and Panacea Biotech were present in the webinar.

 

Growing market

Advertisement

 

    • Rs 38,800 crore Worth of medical devices India imported in FY19

 

    • Rs 12,700 crore Medical devices exported in the same year

 

    • Rs 1.05 trillion Market size of Indian medical devices at retail level

 

    • 85% India’s import dependency for medical devices

 

    • Rs 1.4 trillion Domestic pharma market’s turnover in FY20

 

 

 

Advertisement

 

(Note: This is a Article Automatically Generated Through Syndication, Here is The Original Source

Advertisement

Passionate news enthusiast with a flair for words. Our Editorial Team author brings you the latest updates, in-depth analysis, and engaging stories. Stay informed with their well-researched articles.

3 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

World

New Class-Action Lawsuit Accuses Rivian of Making Materially False and Misleading Statements

Published

on

New Class-Action Lawsuit Accuses Rivian of Making Materially False and Misleading Statements

Electric vehicle manufacturer Rivian has been slapped with a lawsuit which alleged that the company misled the investors with false claims regarding its business, operations and prospects.

The class-action lawsuit made a number of allegations which included overstating the demand of its Electric vehicles and also not making it clear how it will handle the negative and near-term macroeconomic impacts.

The lawsuit also revealed that Rivian’s business was experiencing reduced demands as well as increased customer cancellations precipitated by inter alia, high interest rates.

Advertisement

The orders had significantly reduced and this has significantly reduced the profits and the manufacturing of vehicles in 2024.

Rivian Faces New Class-Action Lawsuit Alleging Deceptive Statements

The lawsuit also alleged that the Company’s public statements were materially false and misleading at all relevant times.

Rivian’s stock, like all other EV startups, has been tanking and this has angered the investors who saw a major portion of their investments eroded and a number of law firms like Bernstein Liebhard LLP announced this week that it has filed a securities class action lawsuit on investors’ behalf.

Advertisement

The lawsuit stated that the EV manufacturer had violated the Securities Exchange Act of 1934 and has asked investors who had bought shares of Rivian Automotive, Inc. between March 1, 2023, and February 21, 2024, to join its suit.

The company’s stocks have fallen and one of the primary reasons was the high interest rates. Rivian’s products are beyond the reach of an average income household.

Also Read: Prime Hydration Faces Lawsuits Claiming Its Sports Drink, Prime Energy, Contains PFAS and Excessive Caffeine

Advertisement

The Rivian’s Electric vehicles target customers were wealthier clients and the spurt in order cancellations means this class is walking away from Rivian’s product.

The stocks of the company were popular for the investors but the reduced demands caused by higher borrowing cost have hit its stock prices badly.

The price war has also affected the EV sector and the company also with its competitors like Tesla has been uniformly affected.

Advertisement

The EV sector marked value has tanked by more than 57% year-to-date.

The chance of a fall in interest rates is not expected since the Federal Reserve will not lower the benchmark interest rate since it could lead to a bout of hyperinflation.

Also another factor which will discourage the Federal Reserve to lower interest rates is the soaring energy prices caused by the war in Ukraine and the Middle East.

Advertisement

Also Read: Lawsuit Claims Kennywood Concealed Steel Curtain Closure to Boost Sales

Continue Reading

World

Lawsuit Claims Kennywood Concealed Steel Curtain Closure to Boost Sales

Published

on

Lawsuit Claims Kennywood Concealed Steel Curtain Closure to Boost Sales

Kennywood’s Steel Curtain roller coaster will not be available this 2024 season, and this has miffed a Kensington man to the extent that he has filed a lawsuit against Kennywood and its parent companies, alleging that the officials had known this fact long before but withheld it to boost season pass sales.

Lawsuit Against Kennywood

The lawsuit, filed in the Allegheny County Common Pleas Court by Joshua Miller and his attorney, John A. Biedrzycki III on Monday, alleges that it was a deliberate attempt to hide the fact to accrue financial benefits by boosting season pass sales.

The lawsuit alleges that Kennywood has created advertising campaigns targeting consumers like Mr. Miller and others to purchase the 2024 season pass under the belief that the benefits included myriad park attractions, including the Steel Curtain.

Advertisement

In the lawsuit, it was revealed that Mr. Miller bought his season pass under the assumption that all rides would be operational.

However, on April 17, three days before the park opened for the season, it was revealed that Steel Curtain would be closed for the season.

The announcement was made by Ricky Spicuzza, the park’s assistant general manager, and the reason for the closure was cited as the coaster undergoing an “extensive modification project.”

Advertisement

Ricky Spicuzza said,

“We understand the frustration many of you have felt not being able to experience the Steel Curtain. On behalf of our entire team, we absolutely share that frustration with you.”

However, the lawsuit contends that the fact was known long before last week that the 220-foot-tall coaster would be out of commission.

The lawsuit states,

Advertisement

“The company withheld this information from season pass purchasers so as not to lose season pass customers, or, alternatively, so as not to offer a discount on season passes due to the unavailability of the Steel Curtain.”

The lawsuit also details numerous violations of the state’s unfair trade practices and consumer protection law. This includes failure to disclose the Steel Curtain’s closure with the full knowledge that the consumer believed that it would be functional for the 2024 season.

The park offered varied passes, which ranged from season passes priced from $109.99 to $239.99.

The lowest endowed pass was the bronze pass, which provided unfettered admission except on certain blackout dates.

Advertisement

The premium range included the platinum pass, which offered year-round admission to Kennywood, Sandcastle, Idlewild, and Palace Entertainment’s Dutch Wonderland in Lancaster.

Additionally, it also offered free parking, discounts on food and retail, and three free guest tickets.

Also Read: Prime Hydration Faces Lawsuits Claiming Its Sports Drink, Prime Energy, Contains PFAS and Excessive Caffeine

Advertisement
Continue Reading

World

Prime Hydration Faces Lawsuits Claiming Its Sports Drink, Prime Energy, Contains PFAS and Excessive Caffeine

Published

on

Prime Hydration

Prime Energy, the sports drink from Prime Hydration, has been hit by a number of lawsuits for containing excessive amounts of caffeine and PFAS. Another lawsuit was filed on April 8 in the Southern District of New York, accusing Prime Hydration, the parent company which manufactures the sports drink, of engaging in misleading and deceptive practices.

Prime Hydration was founded by two Logan Paul and KSI in 2022, and the products became very popular thanks to the huge followings of the YouTubers. However, the company is now facing a slew of lawsuits over the ingredients in their energy and sports drinks.

New Lawsuit Against Prime Hydration

The latest lawsuit, filed on April 8, accuses the company’s 12-ounce energy drinks of containing 215-225 milligrams of caffeine, exceeding the permissible limit of 200 milligrams. The lawsuit was filed by Lara Vera, a resident of Poughkeepsie, New York.

Advertisement

The lawsuit details that the plaintiff had purchased Prime’s Blue Raspberry products on numerous occasions in August 2022 for about $3 to $4 each, unaware that the products contained caffeine beyond the permissible limits. The plaintiff is seeking damages of $5 million from the company. Lara Vera’s lawsuit alleges that Prime advertised 200 milligrams of caffeine, which is equal to six Coke cans or two 12-ounce Red Bulls. One Red Bull can could contain 114 milligrams of caffeine.

Also Read: Johnson Controls subsidiary Tyco Fire Products to pay $750 mn to settle ‘forever chemicals’ lawsuit

The suit also alleges that there are no safe limits of caffeine for children and that caffeine has been indicted for causing tachycardia, headaches, convulsions, tremors, upset digestion, and adversely affecting mental health.

Advertisement

Earlier, Senator Charles Schumer, D-N.Y., had asked the Food and Drug Administration (FDA) to investigate Prime energy drinks in 2023 after reports that the products contained high levels of caffeine. The Senator also accused the company of using vague marketing tactics focused on young people, influencing parents to buy the caffeine-laced drinks for their kids. The lawsuit by Vera also quotes the Senator’s call to the FDA.

Prime is also facing another lawsuit filed on Aug. 2, 2023, in the Northern District of California by the Milberg law firm on behalf of Elizabeth Castillo and others. The lawsuit charges Prime’s products with using flavors containing PFAS, or “forever chemicals.” Forever chemicals are a class of chemicals that are not degraded in the human body or nature and have been indicted as a carcinogenic substance. Independent third-party testing has confirmed that Prime Hydration grape flavor contained PFAS.

Also Read: California mother files lawsuit against Tesla after her 2-year-old child starts Model X and runs over her

Advertisement
Continue Reading

Trending

This will close in 5 seconds